High throughput assay technologies for ion channel drug discovery

Assay and Drug Development Technologies

Volumn 2, Issue 5, 2004, Pages 543-552

  Zheng, Wei ^a   Spencer, Robert H ^a   Kiss, Laszlo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CALCIUM 45; CALCIUM CHANNEL; CALCIUM ION; CELL MEMBRANE PROTEIN; CHLORIDE CHANNEL; CHLORIDE ION; CHLORINE 36; CYCLIC NUCLEOTIDE; GLYCINE; INOSITOL TRISPHOSPHATE; ION CHANNEL; KAINIC ACID; MAGNESIUM ION; N METHYL DEXTRO ASPARTIC ACID; NEW DRUG; NICOTINIC RECEPTOR; POTASSIUM CHANNEL; POTASSIUM ION; RUBIDIUM 86; SEROTONIN 3 RECEPTOR; SODIUM 22; SODIUM CHANNEL; SODIUM ION;

AUTOMATION; BINDING ASSAY; CELL MEMBRANE TRANSPORT; DRUG DESIGN; DRUG TARGETING; ELECTROPHYSIOLOGY; EXTRACELLULAR SPACE; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; INTRACELLULAR SPACE; ION CURRENT; ION TRANSPORT; MEDICAL INSTRUMENTATION; PATCH CLAMP; REVIEW;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; ION CHANNELS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 10244264821     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2004.2.543     Document Type: Review

References (37)

1. Davies NP, Hanna MG: The skeletal muscle channelopathies: distinct entities and overlapping syndromes. Curr Opin Neurol 2003;16:559-568.
2. Mulley JC, Scheffer IE, Petrou S, Berkovic SF: Channelopathies as a genetic cause of epilepsy. Curr Opin Neurol 2003;16:171-176.
3. Pictrobon D: Calcium channels and channelopathies of the central nervous system. Mol Neurobiol 2002;25:31-50.
4. Kullmann DM: The neuronal channelopathies. Brain 2002; 125:1177-1195.
5. Hubner CA, Jentsch TJ: Ion channel diseases. Hum Mol Genet 2002;11:2435-2445.
6. Ben-David J, Zipes DP: Torsades de pointes and proarrhythmia. Lancet 1993;341:1578-1582.
7. Belardinelli L, Antzelevitch C, Vos MA: Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003;24:619-625.
8. Fermini B, Fossa AA: The impact of drug-induced QT interval prolongatin on drug discovery and development. Nat Rev Drug Discov 2003;2:439-447.
9. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003;43:441-461.
10. Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R: Drug induced QT prolongation: lessons from congenital and acquired long QT syndromes. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:327-335.
11. Domene C, Haider S, Sansom MS: Ion channel structures: a review of recent progress. Curr Opin Drug Discov Dev 2003;6:611-619.
12. Galligan JJ: Ligand-gated ion channels in the enteric nervous system. Neurogastroenterol Motil 2002;14:611-623.
13. Bennett PB, Guthrie HR: Trends in ion channel drug discovery: advances in screening technologies. Trends Biotechnol 2003;21:563-569.
14. Netzer R, Bischoff U, Ebneth A: HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Dev 2003;6:462-469.
15. Worley JF, Main MJ: An industrial perspective on utilizing functional ion channel assays for high throughput screening. Receptors Channels 2002;8:269-282.
16. Gonzalez JE, Maher MP: Cellular fluorescent indicators and voltage/ion probe reader (VIPR) tools for ion channel and receptor drug discovery. Receptors Channels 2002;8: 283-295.
17. Wolff C, Fuks B, Chatelain P: Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays. J Biomol Screen 2003;8: 533-543.
18. Gonzalez JE, Tsien RY: Voltage sensing by fluorescence resonance energy transfer in single cells. Biophys J 1995; 69:1272-1280.
19. Gonzalez JE, Tsien RY: Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. Chem Biol 1997;4:269-277.
20. Baxter DF, Kirk M, Garcia AF, Raimondi A, Holmqvist MH, Flint KK, Bojanic D, Distefano PS, Curtis R, Xie Y: A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen 2002;7:79-85.
21. Whiteaker KL, Gopalakrishnan SM, Groebe D, Shieh CC, Warrior U, Burns DJ, Coghlan MJ, Scott VE, Gopalakrishnan M: Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators. J Biomol Screen 2001;6:305-312.
22. Tang W, Kang J, Wu X, Rampe D, Wang L, Shen H, Li Z, Dunnington D, Garyantes T: Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen 2001;6:325-331.
23. Terstappen GC: Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal Biochem 1999;272:149-155.
24. + channels: ion flux studies by atomic absorption spectrometry. Assay Drug Dev Technol 2003; 1:647-654.
25. Scott CW, Wilkins DE, Trivedi S, Crankshaw DJ: A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Anal Biochem 2003;15:319:251-257.
26. Gill S, Gill R, Lee SS, Hesketh JC, Fedida D, Rezazadeh S, Stankovich L, Liang D: Flux assays in high throughput screening of ion channels in drug discovery. Assay Drug Dev Technol 2003;1:709-717.
27. Wang X, Li M: Automated electrophysiology: high throughput of art. Assay Drug Dev Technol 2003;1:695-708.
28. Willumsen NJ, Bech M, Olesen SP, Jensen BS, Korsgaard MP, Christophersen P: High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptors Channels 2003;9:3-12.
29. Laszlo K, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, Schroeder K: High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1:127-135.
30. Schroeder K, Neagle B, Trezise DJ, Worley J: Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 2003;8:50-64.
31. Xu J, Guia A, Rothwarf D, Huang M, Sithiphong K, Ouang J, Tao G, Wang X, Wu L: A benchmark study with SealChip™ planar patch-clamp technology. Assay Drug Dev Technol 2003;1:675-684.
32. Bruggemann A, George M, Man M, Beckler M, Steindl J, Behrends JC, Fertig N: High quality ion channel analysis on a chip with the NPC© technology. Assay Drug Dev Technol 2003;1:665-673.
33. Kutchinsky J, Friis S, Asmild M, Taboryski R, Pedersen S, Vestergaard RK, Jacobson RB, Krzywkowski K, Schrøder RL, Ljungstrøm T, Helix N, Sorensen CB, Bech M, Willumsen NJ: Characterization of potassium channel modulators with QPatch™ automated patch-clamp technology: system characteristics and performance. Assay Drug Dev Technol 2003;1:685-693.
34. Shieh C-C, Trumbull JD, Sarthy JF, McKenna DG, Parihar AS, Zhang XF, Faltynek CR, Gopalakrishnan M: Automated Parallel Oocyte Electrophysiology Test station (POETS™): a screening platform for identification of ligand-gated ion channel modulators. Assay Drug Dev Technol 2003;1:655-663.
35. Joshi PR, Suryanarayanan A, Schulte MK: A vertical flow chamber for Xenopus oocyte electrophysiology and automated drug screening. J Neurosci Methods 2004;132: 69-79.
36. Schnizler K, Kuster M, Methfessel C, Fejtl M: The roboocyte: automated cDNA/mRNA injection and subsequent TEVC recording on Xenopus oocytes in 96-well microtiter plates. Receptors Channels 2003;9:41-48.
37. Stett A, Egert U, Guenther E, Hofmann F, Meyer T, Nisch W, Haemmerle H: Biological application of microelectrode arrays in drug discovery and basic research. Anal Bioanal Chem 2003;377:486-495.